5 completed, 4 active not recruiting, 1 recruiting. 5 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Recruiting 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow VIR-3434: new trials by email Literature Review of VIR-3434 trials Research Report on VIR-3434
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 100 | 2025-08-05 | 2026-01-16 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Tobevibart, Elebsiran - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 124 | 2025-03-12 | 2026-04-08 |
| Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION] VIR-3434 - Hepatitis B, Chronic | Phase 2 | Recruiting | University Health Network, Toronto | 15 | 2024-03-13 | 2025-05-29 |
| Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy VRON-0200-AdC6, VRON-0200-AdC7, VIR-2218 - Chronic Hepatitis B | Phase 1 | Completed | Virion Therapeutics | 35 | 2023-09-26 | 2026-08-19 |
| A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection VIR-3434, VIR-2218, TDF - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Vir Biotechnology, Inc. | 33 | 2023-05-10 | 2026-02-09 |
| Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 VIR-2218, VIR-3434 - Hepatic Impairment, Cirrhosis | Phase 1 | Completed | Vir Biotechnology, Inc. | 88 | 2022-09-21 | 2026-09-09 |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. VIR-2218, VIR-3434, NRTI - Hepatitis D, Chronic | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 95 | 2022-09-17 | 2026-06-26 |
| Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection VIR-2218, VIR-3434, PEG-IFNα - Hepatitis B, Chronic | Phase 2 | Completed | Vir Biotechnology, Inc. | 244 | 2021-07-11 | 2026-04-23 |
| Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection VIR-3434, Placebo - Chronic Hepatitis B | Phase 1 | Completed | Vir Biotechnology, Inc. | 113 | 2020-05-26 | 2024-10-08 |
Hepatitis (7) · Hepatitis B, Chronic (5) · Hepatitis B (4) · Hepatitis D (4) · Hepatitis D, Chronic (4) · Digestive System Diseases (2) · Liver Diseases (2) · Fibrosis (1)
Vir Biotechnology, Inc. (8) · University Health Network, Toronto (1) · Virion Therapeutics (1)
Romania (7) · United Kingdom (7) · Germany (6) · Moldova (5) · New Zealand (5) · France (4) · Hong Kong (4) · Canada (3) · South Korea (3) · Ukraine (3) · United States (3) · Bulgaria (2) · Italy (2) · Netherlands (2) · Pakistan (2)
Jordan Feld, MD (1) · Sue Currie, PhD (1)
PMID 41586499, PMID 40882923, PMID 41211943, PMID 42214405
2019 (1)